Search results

Filters

  • Journals
  • Date

Search results

Number of results: 2
items per page: 25 50 75
Sort by:

Abstract

Background: Recoarctation (reCoA) of the aorta is a common complication after the Norwood procedure. Untreated, it can lead to failure of the systemic ventricle and death. The main goal of the study is to defi ne risk factors of reCoA after the Norwood procedure in hypoplastic left heart syndrome (HLHS). Methods: We retrospectively analyzed the pre-, intra- and postoperative data of 96 successive patients who underwent the Norwood procedure between 2007 and 2011. In case of reCoA balloon angioplasty was performed. We analyzed and compared the data of the patients with reCoA and without reCoA using the StatSoft STATISTICA™ 10 soft ware. Results: ReCoA was noted in 23 patients (33.3%). Th is complication was diagnosed 95.1 days (49–156 days) on the average aft er the Norwood procedure. Balloon angioplasty successfully allowed for decreasing the mean gradient across the site of the narrowing from the average 27.5 mmHg to the average 9.7 mmHg (p = 0.008) and enlarged the neo-isthmus by the average of 2 mm (p <0.05). Th e risks factors seemed to be the diameter of the ascending aorta OR = 7.82 (p = 0.001), atresia of the mitral valve OR = 7.00 (p = 0.003) and atresia of the aortic valve — OR = 6.22 (p = 0.002). Conclusion: Balloon angioplasty seems to be an eff ective intervention in case of reCoA. A low diameter of the native ascending aorta (≤3mm) and the presence of atresia of the mitral and/or aortic valve should intensify the vigilance of a cardiologist in the search for signs of reCoA of the aorta.
Go to article

Abstract

T h e a i m: The aim of the study is to present the initial experience with continuous flow left ventricle assist device (CF-LVAD) in pediatric patients with BSA below 1.5 m2. M a t e ri a l a n d M e t h o d s: Between 2016 and 2017, CF-LVAD (the Heartware System) have been implanted in three pediatric patients in the Department of Pediatric Cardiac Surgery, Jagiellonian University, Krakow, Poland. The indications for initiating CF-LVAD were end-stage congestive heart failure due to dilated cardiomyopathy in all children. R e s u l t s: Implanted patients have had BSA of 1.09, 1.42, 1.2 m2, and 37, 34, 34 kg of body weight and the age 12, 11, 12 years, respectively. The time of support was 550 days in two patients and 127 in another one, and is ongoing. The main complication has been driveline infection. C o n c l u s i o n: The outcomes from our single-center experience using the HeartWare CF-LVAD have been excellent with a low incidence of complication and no necessity to reoperation in our patients. Children could be successfully and safely discharged home.
Go to article

This page uses 'cookies'. Learn more